title: [Studies on 5-FU concentration and thymidine phosphorylase activity in tissues of patients with colorectal cancer after SF-SP administration].
abstract: 5-fluorouracil (5-FU) concentrations in peripheral blood, portal blood, normal and cancer tissues were evaluated in 26 patients with colorectal cancer after SF-SP administration (800 mg/day for 10 days). Thymidine phosphorylase activity in cancer tissues was also evaluated. 5-FU concentration in cancer tissues was significantly higher than that in other three specimens, and much higher than 0.05 microgram/g which was reported to be the minimum effective concentration. 5-FU concentration in portal blood was lower than MEC (0.05 microgram/ml). As for the relationship with the pathological features of cancer, the protruding lesions showed a higher 5-FU concentration than the ulcerative ones, and the lesions invaded only to submucosa or proper muscle showed a higher concentration than others. 5-FU concentration ratio in cancer tissues per in peripheral blood (T/B ratio) was related to thymidine phosphorylase activity. The higher was the thymidine phosphorylase activity, the greater T/B ratio. The results suggest that the tumor with higher thymidine phosphorylase activity might have a more pronounced anticancer efficacy of 5-FU.
authors: First Dept. of Surgery, Kagoshima University School of Medicine.
authors: K
authors: K
authors: Yamada
authors: S
authors: S
authors: Hase
authors: A
authors: A
authors: Yoshimura
authors: K
authors: K
authors: Haruyama
authors: Y
authors: Y
authors: Katsura
authors: T
authors: T
authors: Sameshima
authors: K
authors: K
authors: Niwa
authors: T
authors: T
authors: Ishizawa
authors: H
authors: H
authors: Shimazu
mesh_terms: D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D003131:Combined Modality Therapy; D003692:Delayed-Action Preparations; D005472:Fluorouracil / Q000097:blood / Q000493:pharmacokinetics*; D006801:Humans; D011169:Portal Vein; D005641:Tegafur / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013939:Thymidine Phosphorylase / Q000378:metabolism*; D014018:Tissue Distribution
chemical_list: D003692:Delayed-Action Preparations; D005641:Tegafur; D013939:Thymidine Phosphorylase; D005472:Fluorouracil